rejuvant life tabs

Longevity biotech announces pricing of upsized IPO

Latest articles

Leucine, weight loss and NAD+ boosting

Part 2 of our interview with NuSirt's founder explores clinical trials and commercialisation of nutraceutical and pharmaceutical combinations with leucine. In the first part of...

Organoid to the rescue of the thyroid

Sci-fi or reality? Artificial organs may soon be the solution for those suffering from all forms of hypothyroidism. The role of the thyroid gland is...

Changing demographics warrant solid longevity foundation

EU Green Paper on Ageing is a wish list, but the European Longevity Initiative is proposing a foundation first. Back in January, the European Commission...

Longevity supplements report: JUVICELL profile

Determined to bring longevity opportunities to a wider market, JUVICELL packs ten ingredients into its longevity supplement. Over the coming weeks, we will be bringing...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

Leucine, weight loss and NAD+ boosting

Part 2 of our interview with NuSirt's founder explores clinical trials and commercialisation of nutraceutical and pharmaceutical combinations with leucine. In the first part of...

Organoid to the rescue of the thyroid

Sci-fi or reality? Artificial organs may soon be the solution for those suffering from all forms of hypothyroidism. The role of the thyroid gland is...

Changing demographics warrant solid longevity foundation

EU Green Paper on Ageing is a wish list, but the European Longevity Initiative is proposing a foundation first. Back in January, the European Commission...
Rejuvant

Finch Therapeutics Group announces the pricing of its upsized initial public offering to target $127.5M

Before deducting underwriting discounts and commissions and offering expenses, Finch is expected to receive $127.5 million gross from its IPO. All of the shares of common stock are being offered by Finch, and in addition, Finch has granted the underwriters a 30-day option to purchase up to an additional 1,125,000 shares of common stock at the initial public offering price, less the underwriting discounts and commissions [1].

Longevity.Technology: Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally-administered biological drugs. Developing both complete and targeted microbiome therapeutics, Finch is advancing a pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the FDA.

After the announcement last Thursday, Finch’s shares began trading on the Nasdaq Global Select Market on Friday, 19 March 2021 under the ticker symbol “FNCH.” The offering is expected to close on 23 March 2021, subject to customary closing conditions. BofA Securities, Jefferies and Evercore ISI are acting as joint book-running managers for the offering.

A registration statement relating to the shares being sold in this offering has been filed with the US Securities and Exchange Commission and was declared effective on 18 March 2021. The offering of the shares is being made only by means of a prospectus forming part of the effective registration statement relating to these shares.

Elevant

 


 

“Our IPO is an exciting step that will help fuel our mission to transform lives with microbiome therapeutics.”

 


 

Finch tweeted: “Our IPO is an exciting step that will help fuel our mission to transform lives with microbiome therapeutics. We thank our incredible team members, board members, investors, business partners, and the clinicians and patients that have participated in our clinical trials.”

In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch plans to initiate a Phase 3 trial, referred to as PRISM4, as its second pivotal trial of CP101 for recurrent CDI. Finch is also developing CP101 for the treatment of chronic hepatitis B virus, and FIN-211 for the treatment of the gastrointestinal and behavioural symptoms of autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for the treatment of ulcerative colitis and Crohn’s disease, respectively.

Elevant

[1] https://ir.finchtherapeutics.com/news-releases/news-release-details/finch-therapeutics-announces-pricing-upsized-initial-public

Image credit: Pavel Ignatov / Shutterstock

Comment on this article

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
Rejuvant

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Is nicotinamide riboside a safe and effective way to combat aging?

ChromaDex executive highlights the importance of clinical studies to prove the benefits of NAD+ boosting compound. ChromaDex is the company behind the popular healthy aging...
Supplement report

Related articles

Longevity supplements report: JUVICELL profile

Determined to bring longevity opportunities to a wider market, JUVICELL packs ten ingredients into its longevity supplement. Over the coming weeks, we will be bringing...

Gerostate Alpha opens crowdfunded capital raise

Buck Institute-founded start-up Gerostate Alpha seeks to crowdfund its biotech platform. When Y Combinator so likes your ideas, it gives you $1 million to start...

FOXO announces $10million investment to launch FOXO Life

FOXO Technologies Inc announces closing of $10 million investment to launch FOXO Life; continues commercialising epigenetic biomarker technology. FOXO Technologies Inc has announced that it...

Longevity supplements report: PDLH profile

The company behind Rejuvant, which partnered with the Buck Institute for Research on Aging on its calcium alpha-ketoglutarate longevity supplement. Over the coming weeks, we...

Longevity supplements report: Youth & Earth profile

Youth & Earth is keeping it natural, while slowing down aging. Over the coming weeks, we will be bringing you extracts of 11 company profiles...
Supps report ad middle